Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Frontiers Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota

Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

Exploring the food-gut axis in immunotherapy response of cancer patients

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

T-cell engineering strategies for tumors with low antigen density, and T- cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma – ScienceOpen

INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy

The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies, Cell & Bioscience

Cancers, Free Full-Text

IJMS, Free Full-Text

Gut microbiome correlates of response and toxicity following anti CD19 CAR T cell therapy

Frontiers CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure